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We used microarray analysis to investigate associations between genotypic expression profiles and survival phenotypes in patients with primary
glioblastoma (GBM). Tumor samples from 7 long-term glioblastoma survivors (N24months) and 13 short-term survivors (b9months) were analyzed
to detect differential patterns of gene expression between these groups and to identify genotypic subclasses of glioblastomas that correlate with
survival phenotypes. Five unsupervised and three supervised clustering algorithms consistently and accurately grouped the tumors into genotypic
subgroups corresponding to the two clinical survival phenotypes. Three unique prospective mathematical classification algorithms were
subsequently trained to use expression data to stratify unknown glioblastomas between survival groups and performed this task with 100% accuracy
in validation studies. A set of 1478 genes with significant differential expression ( pb0.01) between long-term and short-term survivors was
identified, and additional mathematical filtering was used to isolate a 43-gene “fingerprint” that distinguished survival phenotypes. Differential
regulation of a subset of these genes was confirmed using RT-PCR. Gene ontology analysis of the fingerprint demonstrated pathophysiologic
functions for the gene products that are consistent with current models of tumor biology, suggesting that differential expression of these genes may
contribute etiologically to the observed differences in survival. These results demonstrate that unique expression profiles characterize genotypic
subsets of primary GBMs associated with differential survival phenotypes, and these profiles can be used in a prospective fashion to assign unknown
tumors to survival groups. Future efforts will focus on building more robust classifiers and identifying additional subclasses of gliomas with
phenotypic significance.
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nervous system gliomas. Standard histopathologic grading
classifies more than 40% of these tumors as WHO Grade IV
(glioblastoma (GBM)), and 95% of patients receiving this diag-
nosis succumb to their disease within 5 years [1–4]. This pre-
valence and high mortality have made GBMs a target of intense
research, but efforts to develop diagnostic and therapeutic mo-
dalities capable of improving outcomes have been confounded by
the complex biology and molecular heterogeneity of these tu-
mors. In recent years, investigations have become increasingly
focused on understanding the molecular biology of gliomas and⁎ Corresponding author. Department of Neurosurgery, Cleveland Clinic,
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doi:10.1016/j.ygeno.2008.01.002have led to the discovery of multiple chromosomal abnormalities,
receptor anomalies, and oncogene and tumor suppressor dysre-
gulations that are characteristic of high-grade gliomas [5–12].
These findings, however, have proven difficult to place in a
clinically relevant context, and the result is a persistent gulf be-
tween GBM research and GBM treatment.
Currently, diagnosis, staging, and prognosis of gliomas are
based upon histopathologic techniques. Subsequent decisions
regarding management are predicated upon the assigned his-
tologic grade. Although molecular assays are beginning to see
routine use in some academic centers and may contribute to
decisions regarding patient management, the gold standard for
glioma staging remains the WHO system of histopathologic
analysis. A significant shortcoming of this system is its in-
herent inability to detect functional differences occurring on the
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for classification can be witnessed clinically in the variable
outcomes and response to therapy characteristic of patients
whose gliomas are assigned a WHO grade of IV (GBM). While
prognosis and response are poor for the majority of these
patients, a small but discrete subgroup of therapeutic responders
and subsequent long-term survivors exists. The inadequacy of
histopathologic grading is evidenced, in part, by the inability to
recognize these patients prospectively.
Over the past several years the concept of using molecular
characteristics to predict clinical differences among glioma
patients better has surfaced, and genomic studies of the gliomas
have begun to appear in the neurooncology literature. Initial
efforts focused on examining one or a few genetic alterations and
analyzing their association with major clinical features. Such
work demonstrated that primary or de novo GBMs typically are
found in older patients with alterations in the epidermal growth
factor receptor (EGFR) but without mutations in p53, while
secondary GBMs tend to arise from gradual progression of
lower-grade lesions with primary p53 mutations but without
changes in EGFR.
DNA microarray techniques and other high-throughput
technologies for genomic analysis permit a more intensive in-
terrogation of the molecular pathogenesis of glioblastoma. Ini-
tial microarray investigations support the belief that gliomas in
general and GBMs in particular are molecularly heterogeneous
tumors and that molecular approaches to classification and
grading may have distinct diagnostic and prognostic advantages
[13–23]. The most fundamental of these studies have demon-
strated the ability to group gliomas into mathematically cohesive
classes based solely upon similarities in gene expression patterns
[13–17]. Additionally, these classes can be used to train math-
ematical algorithms for class discrimination of novel tumors
based upon expression profiles [18]. Subsequent investigations
[19] focused more specifically on class discrimination among
high-grade gliomas and suggested the existence of distinct
molecular subclasses within this one histologic group. All of
these studies were essentially proof-of-principle investigations
demonstrating the potential role for expression profiles as a tool
for glioma classification, but clinical correlations for the iden-
tified subgroups were largely absent.
The vanguard of this research is the search for distinct mo-
lecular subclasses of gliomas that have clinical or prognostic
significance. Correlating clinical data with genomic expression
data has demonstrated that expression profiles may be predictive
of both tumor progression [20] and patient survival [21]. This
is particularly evident when examining expression profiles of
high-grade gliomas, for which molecular subgroups correlate
with differential survival despite the similar histologic grade
[22–24]. These data strengthen the belief that it is possible to use
molecular expression profiles to construct subgroups of high-
grade gliomas that have clinical and prognostic significance.
Phenotype generally reflects genotype, and thus it is logical
that a classification scheme based directly upon the genotype
could more accurately predict survival than one that relies on
surrogate histological markers reflective of the underlying
biology. Similarly, it is not fundamentally surprising that com-paring the transcriptomes of gliomas known to behave dif-
ferently under similar extrinsic conditions reveals a subset of
differentially expressed genes. Accordingly, it appears likely
that molecular methodologies of glioma identification and grad-
ing based upon differential gene expression profiles reflective of
clinically significant phenotypic differences will progressively
replace the traditional histopathologic methods of tumor
grading. As described above, current glioma genomics research
has demonstrated not only that classification based upon expres-
sion profiles is technically possible [18], but also that clinical
behavior may be more accurately predicted by molecular classes
than by the current histological (WHO) grades [21–23]. Classi-
fication schemes based upon expression profiling therefore
have the potential to improve tumor grading, prognostication,
and patient management, and our goal is to help translate this
technology into the clinical arena.
This study examines the expression profiles of 20 primary
GBMs. Thirteen of these tumorswere collected frompatients who
ultimately died early from their disease (“short-term survivors”
(STS)), while the remaining 7 were resected from patients who
subsequently demonstrated prolonged survival (“long-term sur-
vivors” (LTS)). We examined the expression data from these
tumors using two distinct analytic models. First, we used a robust
combination of unsupervised and supervised array analysis
techniques to identify differential patterns of gene expression
that distinguish the LTS from the STS. The set of differentially
expressed genes has potential mathematical significance as the
substrate for prospective class discrimination algorithms and has
potential clinical significance as a reflection of tumor biology.
Second, we used a subset of the expression profiles to train a
variety of prospective mathematical classifiers and then tested the
ability of these tools to use tumor genotype to predict clinical
phenotype. We believe that the analytic model that we have
implemented represents the most comprehensive strategy em-
ployed to date for identification of differential expression patterns
and subsequent phenotypic class discrimination between long-
term and short-term GBM survivors.
Results
Using expression profiles for phenotypic class discovery
Selection of genes differentially expressed between long-term
and short-term survivors
Genes that are differentially expressed between short-term
and long-term survivors serve as the basis for class discovery,
while genes without statistically significant differential expres-
sion do not make meaningful contributions to class discrimina-
tion and interfere with clustering algorithms. Accordingly, the
Student t test (with pb0.01) was used to identify a population
of 1478 genes with statistically significant differential expres-
sion between long-term and short-term survivors to be used as
the basis for subsequent class discovery.
Unsupervised analysis
Unsupervised analysis algorithms employ unbiased searches
for patterns of expression that can be used to develop hypotheses
Fig. 2. Correspondence analysis of samples. Red spheres are long-term survivors,
blue spheres are short-term survivors.
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phenotype. These approaches are useful for identifying expres-
sion patterns within the set of differentially regulated genes that
may have phenotypic significance before any additional clinical
data are factored into the analysis. Five independent unsuper-
vised clustering algorithms successfully separated long-term
from short-term survivors with 100% accuracy. Average linkage
hierarchical clustering of samples divided the LTS group from
the STS group at the most proximal bifurcation of the
dendrogram. Support trees confirmed the LTS vs STS split
held in 99% of the 100 iterations (i.e., 99% support for this
distinction, Fig. 1). The self-organizing tree algorithm (SOTA),
which clusters samples through a deconstructive, “splitting”
process rather than an agglomerative process, also made the LTS
versus STS distinction with 100% accuracy. Correspondence
analysis (CoA) (Fig. 2) and principal components analysis
(PCA) (data not shown), which resolve the majority of the
variability between samples into three composite vectors and
represent the differences in three-dimensional space, clearly
distinguish the LTS from the STS group.
Supervised analysis
Supervised analysis methods exploit known phenotypic
relationships between samples as well as information about
known molecular pathways to identify expression “fingerprints”
that can be used in tumor classification. The simplest supervised
algorithms use basic phenotypic information for discovery of
genotypic classes with phenotypic significance. Our study
population contains two distinct phenotypic subgroups (LTS
and STS), and several minimally supervised algorithms can use
this a priori knowledge of two distinct phenotypic groups toFig. 1. Hierarchical clustering of samples. STS, short-term survivor group; LTS,
long-term survivor group. Numbers in boxes represent the percentage support
for class distinction, derived from the hierarchical clustering support model.
Unique sample identifiers have been removed.guide class discovery. k-means clustering is an iterative process
in which the expression profile of each sample is tested against
a specified number of centroids, and the process repeats until
a “best fit” is achieved and the groups are optimally separated.
k-means clustering with k=2 separates LTS from STS samples
with 100% accuracy. This result is supported by the k-means
support algorithm, which runs the k-means clustering process
multiple times from random starting points to verify the clus-
tering results. Self-organizing mapping (with a two-class, 2×1
matrix) and terrain mapping (Fig. S1), neighbor-based unsu-
pervised algorithms, also demonstrate an STS group and an LTS
group with all samples correctly assigned.
Building a prospective classifier—using genotype to predict
phenotype
The ability to identify a set of genes associated with a
particular phenotype does not necessarily imply that this set will
allow accurate and reliable classification of unknown tumors
into appropriate clinical groups, because the difference between
deconstructing a known expression profile and effectively
searching for patterns within a novel profile is paramount. More-
over, a small set of “highly significant” genes is not necessarily
the best pattern upon which to build a classifier, as this set has
likely undergone multiple iterations of filtering, which tends to
introduce compounding biases. For this reason, algorithms have
been created that use expression data first to define a composite
classification set and subsequently to assign an unknown sam-
ple to a particular group.
A relatively simple example of this type of classifier is the
k-nearest neighbors algorithm. This strategy is essentially an
extension of the k-means approach to clustering, in which a
neighbors-based algorithm using distance metrics assigns an
unknown to one of k (user defined) groups based upon its
relative distance from each group's expression centroid. This
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tumors [18], and here we have applied it in a more focused
fashion to classify subgroups of GBMs. A training set of 7
samples was used to construct the LTS and STS expression
centroids, and the remaining 13 samples, whose expression
profiles were not used to train the classifier, were treated as
unknowns and were prospectively classified. The algorithm
correctly classified 100% of the unknowns into the appropriate
phenotypic group.
A second strategy for prospective classification is discrimi-
nant analysis (DAM). This is a multistep algorithm that first
applies an ANOVA filter to select genes that should be near
optimal for partitioning the unknown samples based upon per-
mutations of gene expression in the training set. Next, a multi-
variate partial least squares method is used for gene dimensional
reduction. This is followed by a quadratic discriminant analysis.
The result is not only classification of the unknowns, but also
identification of the subset of genes whose expression patterns
were most useful for classification. When DAM was applied to
the sample population, again using the 7-member training set
and the 13 unknowns, samples were classified into the LTS and
STS phenotypic groups with 100% accuracy. Additionally,
the resulting list of useful genes generated by this algorithm
was used later to investigate the “survival fingerprint” further
(see below).
A third strategy for classification is the recently described
uncorrelated shrunken centroids (USC) algorithm. This method
was designed with the specific goal of allowing prediction
of phenotypic category of a tissue sample based upon its ex-
pression profile as well as identification of genes relevant to this
classification. The USC method is based upon a shrunken
centroids algorithm but modifies the approach by removing
genes with highly similar expression patters. This therefore
exploits the functional interdependence of genes to reduce the
number of genes used to classify, producing a smaller set of
important genes and improving the accuracy of classification.
USC was applied to our sample population using the 7-member
training set and the 13 unknowns and again resulted in clas-
sification of the unknowns into the LTS or STS group with
100% accuracy. The list of genes used to make these distinc-
tions was also used in investigations of the survival fingerprint
(see below).
Virtual logic machines offer a robust approach to class
discrimination based upon expression profiles. One such algo-
rithm is the support vector machine (SVM), which uses known
relationships between members of a subset of elements coupled
with the expression patterns of all of the elements to create a
training set of numeric weights for each element. In a second
phase, the weights are used to assign discriminators to the ele-
ments, and a binary output results in elements being considered
either “in or out of” the group defined in the initial training
process. The pattern of weights can be retained after training
and used to classify novel elements. We used SVM with the 7-
member training set and the 13 unknowns. Using radial metrics
with a constant of 2 and a width factor of 2, the SVMwas able to
classify the 13 unknowns into the appropriate survival groups
with 100% accuracy.The survival fingerprint—analyzing differential expression
patterns that distinguish survival phenotypes
Identifying genes that distinguish survival groups
Seven distinct clustering algorithms and two support algo-
rithms successfully and accurately distinguished between LTS
and STS samples based on expression profiles. Additionally,
four prospective clustering algorithms exploited known geno-
typic–phenotypic relations to build classifiers that use expres-
sion profiles to classify unknown samples into phenotypic
(survival) groups with 100% accuracy. The next objective was
to determine what patterns of differential gene expression en-
able class discrimination. Identification of this “molecular finger-
print” is essential in the development of clinically useful tools for
molecular classification of GBM.
This was accomplished by first constructing five indepen-
dent lists of differentially expressed genes, each derived from a
different analytical model. These models included both unsu-
pervised class discovery strategies and prospective molecular
classifiers. As each of these algorithms is optimized to identify
genes with unique patterns of differential expression, construct-
ing an expression fingerprint by focusing on the overlap these
lists could exclude potentially important genes that may appro-
priately appear on only one list. Instead, the molecular signature
that we describe is a composite constructed by capturing genes
identified as most significant from each of the five lists.
The first list was constructed by applying a two-tailed t test
( pb0.01) to the total population of 24,421 elements to identify
a group of 1478 genes with statistically significant differential
expression between the LTS and the STS groups (as described
above). Second, the significance analysis of microarrays (SAM)
algorithm, an interactive algorithm that is more versatile and
more robust that the Student t when used with array data, was
also employed to discover genes in the total population with
significant differential expression. More than just a test of sig-
nificance, SAM allows for operator control of the false dis-
covery rate and is applicable even in data sets with missing data
points. Setting the false discovery rate at 2 (genes) identified a
group of 53 genes with highly significant differential expression
between the two groups. These genes comprised the second
gene list. Two additional lists were created by applying the
DAM and USC algorithms to the total population. As described
above, each of these algorithms accurately separated the LTS
from the STS group, and each generates a list of genes that were
most useful for class discrimination. Student's t test ( pb0.05)
was subsequently applied to both lists, generating lists of 8
(from USC) and 28 (from DAM) genes whose differential ex-
pression patterns were both statistically significant and useful
for supervised class discrimination. Six genes failed to achieve
statistical significance but appeared on both the USC and the
DAM list, and these were retained in subsequent analyses as the
fifth and final list.
The five gene lists were combined into a composite gene
list, and this list was then further refined. Redundant entries
were deleted, and genes that appeared only on the pb0.01 list
and not on any additional lists were removed. Next, the mean,
standard deviation, and 95% confidence interval for each
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computed. Genes were deleted (1) if they represented only
ESTs, (2) if the 95% confidence intervals for mean expression
value in the LTS and STS groups intersected, or (3) if the
absolute difference in average expression groups was b0.35
log2 units (~0.27-fold change). Variance of the mean was
calculated as a measure of dispersion for the expression of each
gene within each group, but this value was not used as an
absolute exclusion criteria. The result was a list of 43 genes that
are both differentially regulated and useful for class discrimi-
nation (Table S1, Fig. 3).Fig. 3. Hierarchical tree of survival fingerprint genes only. STS, short-term
survivor group; LTS, long-term survivor group. Unique sample identifiers have
been removed.Verifying expression data
Reverse transcriptase polymerase chain reaction (RT-PCR)
was performed to validate the 43-gene survival fingerprint
described above. Six housekeeping genes were tested empiri-
cally. GAPDH was determined to be the most consistent control
and was used as the reference for all subsequent RT-PCR.
Fourteen genes from the survival fingerprint were selected for
further study (see Table S2). These genes had one or more of the
following attributes: (1) large magnitude of differential regula-
tion between survival groups, (2) narrow variance of magnitude
of relative expression within a given survival group, (3) re-
presentation in multiple GO categories and terms (see below),
and/or (4) known or theoretical pathophysiological significance
in GBM. These criteria were used in an attempt to select high-
quality genes with both biological and statistical significance for
separating the LTS and STS groups.
Expression of the 14 genes was assayed in all 20 glioblastoma
samples, in the pooled LTS and STS samples (two technical
replicates of each, constructed as described above), and in the
control normal brain RNA sample. A total of 280 data points
representing the expression of each gene in each sample (relative
to control) were generated. Internal controls in the RT-PCR
analysis system indicated that 266 of these points represented
reliable data, and these were used for subsequent investigation.
Analysis of the average expression data for each of the 14 genes
across all 20 glioblastoma samples indicated that the direction of
expression of a given gene assayed by RT-PCR (upregulation or
downregulation relative to control) matched the direction of
expression measured by microarray analysis in a mean of 78.7%
of samples. Additionally, the RT-PCR and microarray data
concurred on the direction of regulation in at least 50% of
samples for all 14 assayed genes. Analysis of these data by
sample demonstrated concurrence of RT-PCR and microarray
data for the direction of regulation in a mean of 74.9% of the
genes in each sample. Overall, the RT-PCR and microarray data
demonstrated regulation in the same direction for a total of 197
of the 266 data points assayed (74.1%). Eighty-three (31.2%) of
these data points demonstrated b50% difference in the measured
magnitude of differential gene expression (relative to control),
although comparisons of magnitude of differential regulation
across platforms are subject to multiple sources of error andmust
be interpreted in that context.
Comparison of the differential expression of the assayed
genes between the LTS and the STS groups demonstrated a high
degree of correlation between the RT-PCR (pooled and non-
pooled samples) and the microarray data (Table S3). More than
half of the analyzed genes had differential regulation in the same
direction between phenotypic groups in all three assays (8 of 14;
57.1%). The semiquantitative data also showed a high degree of
correlation between assays. When the mean log2(LTS/STS) was
calculated, the standard deviation, expressed as a percentage of
the mean, was less than 75% for 8 of 14 (57.1%) genes. Simi-
larly, the variance of the mean was b0.1 for 8 of 14 (57.1%)
genes. These data suggest that RT-PCR data, whether derived
from pooled samples or from the average expression of non-
pooled samples, support the qualitative and semiquantitative
microarray data.
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groups
The purpose of this study is to demonstrate the ability to
classify GBMs into subgroups with prognostic significance
based upon the expression profile, and functional analysis of the
expression fingerprint that distinguishes the LTS from the STS
groups is useful for the purpose of further exploring the mo-
lecular biology of the genes that facilitate such classification. If
the fingerprint reflects transcriptome-level changes that serve as
the biological basis for the observed genotypic–phenotypic
correlation, then it would be expected to contain genes having
some pathophysiologic significance. Accordingly, functio-
nal classification of the genes comprising the GBM finger-
print was performed using EASE [45] and DAVID [46] for
Gene Ontology (GO) [47,48] annotation of the gene list. The
resulting data provide insight into the functional significance
of the transcriptome-level changes in cellular processes and
macromolecular localizations that contribute to the survival
fingerprint.
Table 1 lists the 15 most commonly occurring GO terms in
the GO molecular function, biological processes, and cellular
component classes as well as the number of genes matching each
term in the GO annotation of our 43-gene survival fingerprint.Table 1
Representation of GO categories and terms
GO category GO term No. of
genes
Log2
(LTS/STS)
p value
(net differential
regulation)
Molecular
function
Protein binding 15 0.99 0.020
Molecular
function
Calcium ion binding 6 1.31 0.156
Molecular
function
Receptor binding 5 2.08 0.005
Molecular
function
Peptidase activity 5 1.42 0.297
Biological
processes
Cellular protein
metabolism
13 1.02 0.024
Biological
processes
Cell–cell signaling 5 1.60 0.002
Biological
processes
Cell adhesion 5 1.32 0.201
Biological
processes
Monovalent inorganic
cation transport
4 0.600 0.410
Biological
processes
Endocytosis 3 −0.22 0.837
Biological
processes
Sexual reproduction 3 2.08 0.068
Biological
processes
Cell fate commitment 2 1.81 0.199
Biological
processes
Notch signaling
pathway
2 0.45 0.514
Cellular
component
Plasma membrane 12 0.96 0.093
Cellular
component
Integral to plasma
membrane
10 0.98 0.128
Cellular
component
Coated pit 2 0.03 0.988
GO, Gene Ontology project; STS, short-term survivor group; LTS, long-term
survivor group.Additionally, we used the relative expression values of the genes
annotated to each GO term to investigate further the net trend
in expression for that term. This was accomplished by first
averaging the log2 expression ratio relative to control for each
gene and then calculating the mean expression for that gene in
both the LTS and the STS populations. Next, the properties of
log subtraction were used to calculate the relative expression of
each gene in the LTS group relative to its expression in the STS
group. Finally, the mean log2(FILTS/FISTS) for the genes anno-
tated to each GO termwas calculated. The statistical significance
of the differential expression reflected by this mean value was
calculated using the Student t test to compare the mean ex-
pression values for each gene (relative to control) in the LTS and
STS groups.
The results of this analysis demonstrate that genes coding for
cellular elements involved in protein binding, receptor binding,
protein metabolism, and cell–cell signaling have statistically
significant upregulation in the LTS group relative to the STS
group. Differential regulation of additional structural and func-
tional elements is suggested by the additional GO categories
listed in Table 1, although the number of genes assigned to each
category is insufficient to achieve statistical significance.
Discussion
Patient selection and inclusion criteria
Microarray studies conducted for the purpose of class dis-
covery are sensitive to the effects of bias introduced prior to the
data analysis. Erroneous classification often results when as-
sumptions are made in advance regarding the relative im-
portance of a particular gene or group of genes in defining a
functional class or when such assumptions are made part of the
inclusion criteria in a class discovery study. Because of the large
amount of data generated inmicroarray analyses, class discovery
algorithms can often generate groups with distinct and statis-
tically significant differences in expression profiles, but these
groupings may nonetheless be inaccurate or invalid because the
classification is predicated upon faulty assumptions. This is a
well-known problem in molecular class discovery research, and
the solution is to control potential biases aggressively prior to
analysis and to limit or eliminate preconceived assumptions
when designing a class discovery experiment.
This study was constructed with these considerations in
mind, and both the study design and the analytic model were
engineered to limit such biases. Inclusion criteria for this study
were made as broad as possible to limit selection bias. Samples
of primary (de novo) GBMs from adult patients resected prior to
adjuvant therapy were included without regard to the molecular
characteristics of the tumor. This was done in an attempt to
eliminate a priori conclusions regarding clinical significance of
select genes, as the results of EGFR amplification [49] and p53
mutational analyses [1], for example, have proven inconclusive
as to their exact effect in terms of response to therapy or prog-
nosis. The distribution of EGFR and p53 alterations in our
population of STS and LTS patients appears to be random and
not likely to be determinative of the microarray patterns.
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potential effect of prior treatments that may have been
previously administered to patients with secondary GBMs.
Finally, we are also aware that limiting the group to only those
tumors histologically classified as GBMs is a potential source of
bias, as histopathologic classification of gliomas is itself
subjective. A more extensive investigation including all grades
of glioma would be better suited for unbiased class discovery,
but such an analysis was beyond the scope of this proof-of-
principle study. Given that GBM is the most histologically
distinct tissue diagnosis among the gliomas, we believe the
chance of including a “lower grade” tumor is minimal. We
therefore believe that these inclusion criteria limit selection bias,
but we are aware that the chance of such bias is not zero.
Differences in extent of initial resection between survival
groups
Examination of the demographic data for the LTS and STS
groups demonstrates that the only statistically significant dif-
ference between groups was the extent of the initial tumor
resection. One hundred percent of patients in the LTS group had
surgical intervention resulting in either gross total resection or
near-total resection, but this result was achieved in only 46% of
STS patients. Extent of resection is correlated with survival in
patients with malignant gliomas [50], but the pathophysiologic
nature of this relationship remains unclear. While one inter-
pretation of this finding is that an increased number of residual
tumor cells leads to earlier recurrence, another possibility is that
the phenotypic correlations of the tumor genotype (i.e., growth
rate, location, degree of microinvasion) ultimately affect the
resectability of the tumor. The relatively small sample sizes in
each group should also be considered when interpreting these
data, and the extent to which this trend is apparent in the overall
populations of long-term and short-term survivors cannot ne-
cessarily be extrapolated from these data. We are optimistic that
future, large-scale investigations will help to clarify further the
true nature of this observation.
Without more extensive knowledge of the quantitative rela-
tionships of both extent of resection and tumor genotype on
overall survival, an appropriately constructed multivariate sur-
vival analysis cannot be performed. Nonetheless, we felt that it
was important to investigate the degree to which extent of re-
section affected our class discovery, our prospective tumor
classifiers, and our survival fingerprint. We therefore repeated
the analysis outlined above after subtracting data from the seven
STS patients who underwent subtotal resection. The population
for this redo analysis therefore consisted of samples from seven
LTS and six STS patients (n=13).
The class discovery results were identical to those described
above, with hierarchical clustering (HCL), support tree algo-
rithm (STA), SOTA, PCA, CoA, k-means clustering (KMC),
and terrain mapping (TM) algorithms all separating the LTS
from the STS group with 100% accuracy. The prospective
classifiers performed nearly as well, with k-nearest neighbor
clustering (KNNC), DAM, and USC classifying unknowns with
100% accuracy and SVM misclassifying only 1 of 7 unknowns.We believe that this slight increase in the SVM error rate may be
attributable to the smaller number of samples available for con-
struction of the training set. The survival fingerprint was also
similar in composition, but contained approximately half as
many genes. The genes that were absent after this redo analysis
were generally those in the original survival fingerprint with
smaller relative expression differences between LTS and STS.
This effect is not surprising, given that data are available from
fewer samples to contribute to the two-sided t test. The relative
differences in these “borderline” genes may therefore fail to
achieve statistical significance after expression data from six
samples are subtracted, and thus the genes are excluded from
the fingerprint. We believe that the high degree of correlation
between class discovery, prospective classification, and gene
identification in the original and the redo analyses argues for at
least some degree of pathophysiologic contribution to the dif-
ferential survival, rather than simply reflecting the effects of
extent of tumor resection.
Class discovery
A two-tiered data analysis strategy was used for class dis-
covery. The initial analysis employed unsupervised class
discovery algorithms, including hierarchical clustering, the sup-
port tree algorithm, the self-organizing tree algorithm, corre-
spondence analysis, and the analysis of principal components.
Because the initial two-tailed t test that defined the population of
genes used as the basis for this class discovery was performed
such that genes with differential expression between two known
phenotypic groups were selected as the substrate for subsequent
class discovery, we are aware that this initial analysis is not
absolutely unsupervised in the strictest sense. It is, however,
unsupervised in that no information regarding the phenotype of
any individual sample was used to influence class discovery.
The unsupervised clustering algorithms used unbiased
searches for patterns of expression to cluster samples based
purely upon their genotype. Each of the five algorithms inde-
pendently identified a fundamental distinction between two
unique genotypic subgroups within the sample population. The
final assignment of samples into these two subgroups was
identical for all five algorithms, supporting the hypothesis that
the sample population contains at least two unique genotypic
groups. Subsequent phenotypic analysis demonstrates that one
of the primary genotypic subgroups comprises the samples from
all 7 long-term survivors, while the other genotypic subgroup
contains the samples from all 13 short-term survivors. The
unsupervised analysis therefore demonstrates the presence of
two unique genotypic groups within the sample population and
suggests a phenotypic correlation for these groups.
The supervised analysis was predicated upon the knowledge
that two distinct phenotypic groups existed in the sample
population. Using only the a priori knowledge of the number of
subgroups, the KMC, self-organizing maps (SOM), and TM
again demonstrated phenotypically similar samples clustered
together into two distinct genotypic groups with 100% accu-
racy. This supports the hypothesis that there are fundamental
differences in the transcriptomes of GBMs from patients in the
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algorithms can use these genomic expression differences to
cluster samples into groups with phenotypic significance.
Finally, we demonstrated, using four different algorithms,
that the genomic expression patterns that characterize the two
survival groups can be used to train mathematical classifiers that
are subsequently able to classify unknowns into genotypic
groups with phenotypic correlations. KNNC is the least user-
dependent algorithm, having a minimal number of parameters
to adjust prior to training and classification. This is attractive
because it limits operator bias, but it also minimizes the extent
to which the algorithm can be customized. While the DAM
algorithm is optimized for class discrimination among three or
more classes, the results were favorable and the gene list gen-
erated by the algorithm was useful in constructing the ex-
pression fingerprint. The USC and the SVM methods can be
adjusted to allow accurate classification of unknowns while
minimizing overclassification, and the SVM classification table
can be saved for future use on a novel population of unknown
samples. These strategies represent the newest direction in
genome-based prospective classification strategies, and we have
demonstrated that they are potentially useful for constructing
prospective, molecular classifiers capable of distinguishing
subgroups of gliomas with phenotypic significance.
Differential genomic variability between phenotypic groups
An interesting effect observed in the course of analyzing the
expression profiles of samples in the LTS and STS groups is the
differential variability of the expression profiles within each
subgroup. The PCA and CoA plots of the LTS group de-
monstrate a high degree of similarity in the overall expres-
sion signature of these samples, with most of the variability
represented along a single axis of the 3D plots (Fig. 2). The
opposite is true of the STS group, in which there is signifi-
cant spread along all three axes. This effect is also noted in the
SOTA analysis, by which the LTS samples cluster early into one
large group, while the STS samples stratify into multiple sub-
groups of one or two samples each. These findings suggest
that the members of the STS group may have a high degree of
individual genomic variability, while the LTS group demonstrates
a more cohesive overall pattern of expression suggestive of fun-
damental genomic similarity among members of the group.
This finding is also significant considering the mechanism
by which class assignments are made for novel samples. It
appears that the LTS phenotype correlates with a distinct geno-
typic signature, whereas the STS phenotype reflects expression
patterns that are “everything else.” If this is the case, then the
ability of the prospective classifiers to assign a novel sample to a
survival group may be predicated upon a simple “in-class”
versus “out-of-class” call for the unknown expression profile,
relative to the LTS expression fingerprint. This concept is
similarly illustrated by the CoA plot, in which the expression
differences distinguishing the survival groups are reflected
purely by position along the x axis (axis 1). The remainder of
the genotypic variability does not contribute to the in-class or
out-of-class distinction.The physiologic correlation of this observation is also
important when interpreting these findings. One interpretation
of the above observations is that the LTS profile reflects a
unique subclass of GBMs that are somehow inherently less
aggressive (slower replication, less invasive, etc.). These tumors
would therefore be expected to grow and to recur more slowly,
and the survival fingerprint reflects expression patterns that
facilitate this inherently more gradual tumor progression. An
alternate interpretation of the data suggests that the survival
fingerprint is characteristic of a GBM subgroup that has im-
proved response to initial adjuvant therapy and thus enjoys
prolonged survival. This conclusion is based upon the obser-
vation that all of the patients included in this study underwent
adjuvant therapy following the initial resection, usually con-
sisting of XRT + Temodar. Overall, patients in the LTS group
responded well to adjuvant therapy, as evidenced by an in-
creased time to progression as well as a prolonged survival time.
Patients in the STS group may have received relatively less
benefit from similar adjuvant therapy, reflected by relative
decreases in the same clinical parameters. This suggests that the
survival fingerprint may reflect an expression pattern that makes
the tumor cell relatively more sensitive to radiation damage and
alkylators and therefore ultimately prolongs survival. This study
has not been specifically designed to investigate this question
further, but we intend to pursue future investigations that further
investigate the existence and nature of such “response to
therapy” expression profiles.
Functional significance of the survival fingerprint
The 43 differentially regulated genes in the survival finger-
print code for proteins involved in signal transduction, second-
messenger pathways, extracellular matrix interaction, cellular
growth and metabolism, and stress response. Subjective review
of this gene list suggests that differences in response to immu-
nologic signaling, extracellular interactions, and cell metabo-
lism may contribute to the differences in clinical outcomes
observed in these phenotypic subsets of GBM patients. Relative
upregulation in the LTS group of genes coding for proteins
involved in cell–cell signaling and in second-messenger
pathways may suggest that these cells are more responsive to
extrinsic signaling, more susceptible to immune modulation, or
have less dysregulation of normal cellular processes. This, in
turn, may contribute to the relative increase in survival observed
in the LTS group.
A more objective analysis of the functional significance of
the survival fingerprint was performed using EASE and DAVID
to assign GO annotations to the 43 genes in the profile. The
degree of net differential regulation of the genes associated with
each GO term was calculated (as described above) and tested for
statistical significance. This analysis demonstrated statistically
significant upregulation of the receptor binding, protein
binding, cellular protein metabolism, and cell–cell signaling
GO terms in the LTS subgroup. While the magnitude of the net
differential regulation of these terms is prone to biases in-
troduced by overclassification, the trends illustrated by this
approach lend further support to the hypothesis that GBM cells
Table 2
Demographics and treatment
LTS STS p value
Number of patients 7.00 13.00
Age (mean) 57.71 64.00 0.2259
Age standard deviation 8.50 13.85
Age 95% CI 6.30 7.53
Sex (% female) 0.57 0.77
Sex (% male) 0.43 0.23
Survival (mean) (months) 29.09 5.53 0.0000
Survival standard deviation 4.29 3.13
Survival 95% CI 3.18 1.70
No. (%) GTR 4 (57%) 3 (23%)
No. (%) NTR 3 (43%) 3 (23%)
No. (%) STR 0 (0%) 7 (54%)
Resections (mean) 1.43 1.15 0.2567
Resections standard deviation 0.53 0.38
Resections 95% CI 0.40 0.20
Initial intervention was resection 7 (100%) 13 (100%)
Postresection XRT 7 (100%) 11 (85%)
Total dose (mean) 53.30 49.28 0.5704
Dose fractions (mean) 34.25 24.80 0.3845
Adjuvant chemotherapy 7 (100%) 9 (69%)
Additional chemotherapy 5 (71%) 6 (46%)
Chemotherapy modalities (mean) 2.86 1.00 0.0325
Chemotherapy modalities standard deviation 1.77 0.82
Chemotherapy modalities 95% CI 1.31 0.44
Recurrence/progression (radiographic) 6 (86%) 9 (69%)
Recurrence/progression
unknown/not documented
1 (14%) 4 (31%)
Time to recurrence/progression (mean) (months) 7.28 2.40 0.0414
Time to recurrence/progression
standard deviation (months)
4.41 1.91
Time to recurrence/progression 95% CI
(months)
3.26 1.04
CI, confidence interval; GTR, gross total resection; NTR, near-total resection;
STR, subtotal resection; XRT, radiotherapy.
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lation and may have less dysregulation of normal cellular phy-
siologic processes.
We note, however, that this experiment was designed to
maximize the potential for clinically relevant, phenotypic tumor
classification and that it has not been optimized for the study of
tumor biology. As such, it is possible that functionally signifi-
cant genes do not appear in this profile, and it is also possible
that some genes in this profile reflect expression in the tumor
microenvironment rather than in the transformed astrocyte.
Additionally, the nature of the algorithms used to identify genes
for this list may have excluded some genes with physiologic
significance in exchange for genes with more a statistically
significant contribution to class discovery. We therefore have
been careful to avoid drawing excessive conclusions regarding
the role of the specific genes comprising the profile, and we do
not suggest that the presence or absence of any particular gene
in the fingerprint be overly scrutinized. The genes in this mo-
lecular signature seem to be useful for classification, and their
products have functions that fit with current paradigms of tumor
cellular biology. However, detailed conclusions regarding their
functional significance are premature.
Conclusions
We used microarray analysis to investigate the association
between genotypic expression patterns and survival phenotype
in patients with a primary glioblastoma. We demonstrate that
GBM tumor genotype corresponds with survival phenotype and
that expression data can be used to classify GBMs into genomic
subgroups with phenotypic significance. Class discrimination
can be performed prospectively, using previously trained classi-
fication algorithms, and this strategy can be used to assign
unknown tumors into genotypic subgroups that associate di-
rectly with the survival phenotypes. A population of at least 43
genes is differentially expressed between long-term and short-
term glioma survivors, and the expression patterns of these
genes contribute to these class distinctions. In addition, these 43
genes code for proteins that may be functionally significant in
the molecular genesis of GBMs. Future work is focused on
building more robust classifiers and identifying additional sub-
classes of gliomas with phenotypic significance from a larger,
unknown series of GBMs. Such classification tools can be used
both as a method to discriminate LTS and STS patients at the
time of diagnosis—which may prove useful in future human
trials—and to explore the significance of select gene products as
potential biological targets for novel therapeutics.
Materials and methods
Inclusion criteria
Patients selected for inclusion in this study had a confirmed diagnosis of
primary (de novo) glioblastoma and were at least 18 years of age at the time of
diagnosis. Tissue samples were obtained during initial resections of newly
diagnosed GBMs performed as part of standard medical management of this
disease between December 2002 and January 2006. Patients were eligible for
this study if their documented survival was either ≤9 months (short-termsurvivor) or ≥24 months (long-term survivor) from initial diagnosis. Patients
were excluded if they had undergone prior radiation, chemotherapy, or surgical
resection for their GBM. Patients were also excluded if the available clinical
information was insufficient to verify study eligibility or if the pathologic
specimen was inadequate for microarray analysis.
We chose patients with a primary GBM to avoid the effects of prior
treatment (chemotherapy, radiation), which can influence tumor behavior at both
the gene and the protein expression level [25,26].
Sample selection
The Brain Tumor Institute database was queried to generate a list of all
patients meeting the inclusion criteria. The electronic medical records of these
patients were then reviewed to verify study eligibility. Dates of death were
confirmed by querying the Social Security Death Index. Seven long-term
survivors meeting all inclusion criteria were included in this study. Eligible
short-term survivors were randomized using a random number generator, and
tissue from 13 was subsequently selected for inclusion. This study was approved
by the Cleveland Clinic Institutional Review Board.
Tissue samples from the 20 selectedGBMswere originally collected at the time
of surgery following the Brain Tumor Institute's standard operating protocols. All
samples used in this study were flash frozen as quickly as possible after resection
and were subsequently stored at –80 °C until RNA extraction was performed.
Demographics
Demographic information for the LTS group and the STS group are sum-
marized in Table 2. The mean ages of patients comprising the LTS and STS
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female/43% male, and the STS group was 77% female/23% male. The mean
survival was 29.1 months (±3.1, 95% CI) for the LTS group and 5.5 months
(±1.7, 95% CI) for the STS group ( pb0.0001).
All patients except two underwent initial attempted gross total resection at our
institution as the initial therapeutic intervention. Both of the exceptions were
patients in the STS group. One underwent open biopsy followed by gross total
resection, and the other had an incomplete resection at an outside institution and
underwent reoperation with gross total resection at our institution approximately
2 weeks later. The extent of resection in all patients was assessed on postoperative,
contrast-enhanced MRI or CT imaging. We defined gross total resection (GTR) as
absence of residual lesional enhancement, near-total resection (NTR) as trace
amounts of residual enhancement without obvious residual tumor mass, and
subtotal resection (STR) as obvious residual, enhancing tumormass, with resection
of N88% of original tumor [4]. Using this definition, GTR or NTRwas achieved in
seven (100%) patients in the LTS group and in six (46%) patients in the STS group.
STR was performed in the remaining seven (54%) STS patients.
All patients included in this study were initially managed with the goal of
receiving maximal medical and surgical management for their tumors, and an
intent-to-treat model was followed. The mean number of total surgical resections
performed per patient was 1.43 (±0.4, 95% CI) in the LTS group and 1.15 (±0.4,
95% CI) in the STS group ( p=0.26). Postoperative radiation therapy (XRT) was
used in 7 (100%) LTS patients and 11 (85%) STS patients. Two STS patients did
not receive XRT; one ultimately refused and the other died prior to initiation of
therapy. XRT dosimetry data demonstrate that LTS patients received a mean total
dose of 53.3 Gy in a mean of 34.3 fractions, and STS patients received a mean of
49.3 Gy in a mean of 24.8 fractions (p=0.57 and p=0.38). Adjuvant chemo-
therapy was used in 7 (100%) LTS patients and 9 (69%) STS patients. Two of the
4 STS patients who did not receive adjuvant chemotherapy refused this modality,
and 1 underwent adjuvant local radiotherapy with a GliaSite device. Chemo-
therapy data were unavailable for the fourth patient.
Follow-up imaging was available for six (86%) LTS patients and nine (69%)
STS patients. Radiographic evidence of recurrence or progression was de-
monstrated in these patients at a mean of 7.3 months (±3.3, 95% CI) for patients
in the LTS group and at a mean of 2.4 months (±1.0, 95% CI) for patients in the
STS group (p=0.04). With the exception of one current survivor, all patients
ultimately died of their disease. Progression is therefore assumed to have oc-
curred in the remaining one LTS patient and four STS patients despite the
unavailability of imaging.
Data from molecular genetic assays routinely performed on brain tumor
specimens at our institution were collected from the immunohistochemistry
results reported in the clinical pathology reports for all tumors included in this
study. Loss of chromosome 1p, loss of chromosome 19q, EGFR amplification
status, and maximum Ki-67 index were not significantly different between the
STS and the LTS groups. TP53 immunopositivity, a marker for the presence of
TP53 mutations (for which 0–50% staining represents the presence of wild-type
p53 alleles and 50–100% staining represents the presence of mutated p53
alleles) [27], suggested a predominance of wild-type p53 in both survival groups
(Table 3).
Histologic examination
Flash-frozen tissue samples were removed from 80 °C storage and were
immediately embedded in OCT medium. Representative 16-μm sections (twoTable 3
Summary of molecular genetics of samples by survival group
Mean STS Mean LTS p value (STS vs LTS)
1p loss 0.00% 0.00%
19q loss 15.40% 0.00%
EGFR amplified 33.33% 14.29%
Ki-67 index (max) 33.78 12.20 0.13
p53 (max) 17.78 49.17 0.11
STS, short-term survivor group; LTS, long-term survivor group; 1p, chromo-
some 1p; 19q, chromosome 19q; EGFR, epidermal growth factor receptor.replicates) were cut from the embedded tumor block. Each tissue block was
returned to 80 °C storage immediately after sectioning to minimize any po-
tential RNA degradation that may result from tissue warming. Frozen sections
were then stained with hematoxylin and eosin following standard protocols and
were examined using transmitted light microscopy. Samples were reviewed prior
to RNA extraction and confirmed to contain 90% or more viable (nonnecrotic)
tumor cells.
RNA extraction and purification from tissue samples
RNA extraction was performed using a modification of the TRIzol method
optimized to maximize the extraction of high-quality RNA frommammalian brain
tissue (data not shown). Briefly, mechanical homogenization in TRIzol reagent was
used to disrupt and lyse small surgical biopsy samples of GBM tissue. This was
followed by purification with serial extractions and Qiagen RNEasy spin column
cleanup. The quantity, quality, and integrity of the RNA were verified using the
NanoDrop spectrophotometer and the Agilent Bioanalyzer 2100. The detailed
protocol is described in the supplemental material.
Control RNA
Ambion's FirstChoice human brain reference RNAwas used as the experi-
mental control. This RNA represents normal, whole-brain, total RNA extracted
from 26 unique brains and pooled after extraction. Control RNA was analyzed
using the NanoDrop spectrophotometer and the Bioanalyzer 2100 as described
above.
Microarrays
RNA (3 μg) from the GBM samples and the controls was used as the starting
material for synthesis of cDNA target. Target preparation, labeling, and
hybridization were performed according to standard Affymetrix protocols by the
Gene Expression and Genotyping Facility of the Comprehensive Cancer Center
of Case Western Reserve University and University Hospitals of Cleveland. All
samples were hybridized to the Affymetrix Human Genome U133A Plus 2.0
array, which returns expression data for 24,421 unique genes. Two replicate
hybridizations were performed for the control RNA, giving a total of 22 micro-
arrays performed for this study (13 STS, 7 LTS, 2 control).
Real-time RT-PCR
Real-time RT-PCRwas performed to validate the relative expression levels of
a subset of 15 genes (ANK1, APP, BMX, CD34, GBAS, HSPA1B, IL13, IL17,
ITGA6, JAG2, MMP4, NOS2, RPL10, SOX4, UCP3) included in the survival
fingerprint. The TaqMan assay (Applied Biosystems) was used in conjunction
with the ABI Prism 7900HTsequence detection system (Applied Biosystems) to
measure the expression of each of the 15 genes in each of the 20 tumor samples
and in two technical replicates of the control. All assays were performed using
3 μg of total RNA from each sample. Additionally, a pooled sample of LTS RNA
was constructed by combining 1 μg of RNA from each of the 7 LTS samples, and
a pooled sample of STS RNAwas constructed in a similar fashion using RNA
from the 13 STS samples. Expression levels of each of the 15 genes were also
tested in these pooled samples, as an additional method for examining the mean
expression of each gene in each phenotypic subclass. Relative expression for
each gene in each sample was calculated relative to the expression in the control,
and differential expression was calculated by comparing the mean relative
expression for each gene in the LTS versus the STS group.
Data analysis
Following hybridization, fluorescence for each array element was quantified
and the resulting data were examined using Affymetrix GCOS. Quality control
checks were verified and the array data were normalized using the Affymetrix
GCOS software. The average value of the normalized fluorescence intensity for
each gene in the technical replicates of the control sample was computed, and the
ratio of the normalized fluorescence intensity for each gene in each GBM sample
was calculated relative to the corresponding average control intensity. This ratio
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sample was used in subsequent analyses.
Expression data were analyzed using TIGR Multiple Experiment Viewer
[28]. Euclidean distance metrics were used for all calculations, and default
algorithm parameters were used unless otherwise indicated. Genes for which
expression data were available in at least 94% of samples were included for
subsequent analysis. Filtering for statistically significant genes was performed
using the Student t test and the SAM algorithm [29]. HCL of experiments using
average linkage clustering was used to group samples in an unsupervised fashion
[30]. The STA uses bootstrapping of samples (resampling with replacement) to
assign relative likelihoods to hierarchical clustering dendrograms and was used
to validate the HCL results [31]. Additional unsupervised clustering was per-
formed using the SOTA [32,33], PCA [34], and CoA [35]. Supervised analysis
for class discrimination was conducted using KMC with k-means support [36],
SOM [37,38], and TM [39]. Supervised prospective class assignment was per-
formed using KNNC [40], DAM [41], USC [42], and an SVM [43,44]. A
random-number generator was used to select 3 members of the LTS group and 4
members of the STS group as the training set for all prospective classification
algorithms, and the remaining 13 samples (4 LTS, 9 STS) were treated as un-
knowns and were used to test the classifiers.
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